ArticleJournal of medical biochemistry2026
Analysis of the effect of platelet-derived growth factor combined with T cells in the diagnosis of hepatocellular carcinoma and prognostic assessment: A prospective cohort study.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study is to investigate the diagnostic and prognostic value of combined detection of serum platelet-derived growth factor (PDGF) and Treg/Th17 in hepatocellular carcinoma (HCC). Methods: We included 204 HCC patients managed with drug eluting beads-transcatheter arterial chemoembolization (D-TACE) and 100 healthy controls. Serum PDGF concentrations were measured via enzyme-linked immunosorbent assay (ELISA), while flow cytometry quantified Treg and Th17 cell proportions. The predictive performance of PDGF, Th17/Treg, and their combination for HCC diagnosis, therapeutic response, and 1-year overall survival (OS) was evaluated using receiver operating characteristic (ROC) analysis, Kaplan-Meier survival curves. Results: HCC cases exhibited notable elevations in serum PDGF concentrations and Th17/Treg than healthy controls, with tumor tissue PDGF expression significantly correlating with serum levels (P < 0.05). In addition, we found a positive correlation between PDGF, Th17/Treg and tumor markers in HCC patients (P < 0.05). PDGF + Th17/Treg detection yielded an area under the curve (AUC) of 0.835 (68.14% sensitivity, 82.00% specificity), surpassing individual markers. For predicting D-TACE non-response (progressive disease, PD), the combined detection showed 71.70% sensitivity and 84.11% specificity. The 1-year OS rates of the high PDGF group and the high Th17/Treg group were 75.19% (97/129) and 61.22% (30/49), respectively, while the 1-year OS rates of the low PDGF group and the low Th17/Treg group were 92.00% (69/75) and 87.74% (136/155), respectively (P < 0.05). The AUC of the combined model for predicting death was 0.705. Conclusions: PDGF combined with Th17/Treg showed excellent diagnostic value for the occurrence and poor prognosis of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.